Biogen’s Spinraza, positive data in SMA

Biogen presented new data from the Phase III ENDEAR study of Spinraza (nusinersen), which demonstrated a significant reduction in the risk of death or permanent ventilation in infants with SMA (spinal muscular atrophy) treated with Spinraza vs the untreated group. The data were presented at the British Paediatric Neurology Association annual conference. ENDEAR was a randomized, double-blind trial in patients with infantile-onset SMA.
(Source Business Wire)